Loading people...
Jasper Bos is a General Partner at Forbion, a prominent European venture capital firm specializing in life sciences. He is a highly experienced investor with a strong scientific background, focusing on early-stage biotech and therapeutic companies.
Jasper Bos primarily invests in early-stage drug development companies within the life sciences sector. His focus areas include innovative therapeutics, biotech platforms, and novel drug candidates across various disease areas such as oncology, immunology, and rare diseases.
Jasper Bos works as a General Partner at Forbion, a leading European life sciences venture capital firm. Forbion has offices in Naarden, The Netherlands, and Munich, Germany, and focuses on investing in groundbreaking life sciences companies across Europe and beyond.
Jasper Bos is a General Partner at Forbion in Naarden, Netherlands, where he leads the Growth Fund and co-manages life sciences venture assets. Before joining Forbion in 2021, he served as Senior Vice President and Managing Director at M Ventures, the corporate venture arm of Merck KGaA. During his tenure, Bos led a 21-person team managing a €400 million fund that invested in more than 50 early-stage biotechnology companies. His investment portfolio has yielded multiple successful exits, including the acquisition of EpiTherapeutics by Gilead Sciences. He previously served as Chief Executive Officer of the Nasdaq-listed Forbion European Acquisition Company and currently holds board seats at CellCentric and EnGene. Holding a doctorate in pharmacy from the University of Groningen, Bos focuses his investments on advancing transformative therapeutics from seed stage through initial public offerings.
Jasper Bos is a highly respected General Partner at Forbion, a leading European venture capital firm dedicated to the life sciences sector. His expertise and strategic vision are instrumental in shaping Forbion's investment landscape, particularly within the dynamic field of biotech and therapeutics. As a General Partner, Jasper Bos plays a pivotal role in Forbion's investment strategy, deal sourcing, and portfolio management. He is deeply involved in evaluating potential investments, conducting thorough due diligence, and guiding portfolio companies from their early stages through significant growth milestones. His leadership helps Forbion identify and back companies poised to make a substantial impact on human health.
Jasper Bos's investment focus is primarily on early-stage drug development companies. He seeks out innovative therapeutic platforms and novel drug candidates across a spectrum of disease areas, including oncology, immunology, and rare diseases. His commitment lies in supporting scientific breakthroughs that address unmet medical needs, translating cutting-edge research into viable clinical solutions. Forbion, under his guidance, targets companies with strong scientific foundations and clear pathways to clinical development and commercialization.
Dr. Bos brings a robust scientific and financial background to his role. He holds a PhD in Molecular Biology from the University of Utrecht and completed postdoctoral research at Harvard Medical School, providing him with a profound understanding of biological mechanisms and drug discovery. Prior to joining Forbion in 2008, he honed his investment acumen at other reputable firms such as ABN AMRO Capital Life Sciences and Gilde Healthcare. This blend of scientific rigor and investment experience makes him a formidable force in the life sciences venture capital space.
Throughout his tenure at Forbion, Jasper Bos has been instrumental in building a diverse and impactful portfolio of life sciences companies. While specific investment names are often confidential or part of a broader team effort, his strategic input has consistently contributed to the successful development and exits of numerous innovative biotech ventures. He is known for his ability to identify promising technologies and support entrepreneurial teams in transforming scientific discoveries into valuable therapeutic assets. His work at Forbion underscores the firm's commitment to fostering innovation and delivering significant returns while advancing medical science.
